<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01054768</url>
  </required_header>
  <id_info>
    <org_study_id>2009-003</org_study_id>
    <secondary_id>1R21AT004493-01</secondary_id>
    <nct_id>NCT01054768</nct_id>
  </id_info>
  <brief_title>Antioxidant Therapy to Reduce Inflammation in Sickle Cell Disease</brief_title>
  <official_title>Antioxidant Therapy to Reduce Inflammation in Sickle Cell Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UCSF Benioff Children's Hospital Oakland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Center for Complementary and Integrative Health (NCCIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>UCSF Benioff Children's Hospital Oakland</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether alpha-lipoic acid and acetyl-L-carnitine&#xD;
      will lower systemic inflammation in patients with Sickle Cell Disease by reducing oxidative&#xD;
      stress, which will result in a decrease in the frequency of vaso-occlusive pain episodes and&#xD;
      improve their quality of life.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      People with sickle cell disease have more inflammation (a response of body tissues to injury&#xD;
      or irritation) than people without sickle cell disease. This inflammation can be measured in&#xD;
      the blood by checking the level of a protein called C reactive protein as well as other&#xD;
      changes we see in blood due to inflammation (such as changes in platelets and other cells).&#xD;
      There is even more inflammation during sickle-related complications (like pain or acute chest&#xD;
      syndrome). We want to test if inflammation in people with sickle cell disease can be reduced&#xD;
      by the use of antioxidant compounds.&#xD;
&#xD;
      Antioxidants are nutrients (certain vitamins, minerals and enzymes) that can counteract the&#xD;
      effects of oxidative stress arising from free radicals in our cells. The formation of free&#xD;
      radicals is a normal cell process, but uncontrolled oxidative stress can cause problems for&#xD;
      us. One such harmful problem is inflammation.&#xD;
&#xD;
      We know from other research studies that antioxidants help with some conditions related to&#xD;
      inflammation. In this study the antioxidant being tested is a combination of alpha-lipoic&#xD;
      acid and acetyl-L-carnitine, both of which are natural parts of many of the foods we eat and&#xD;
      are needed by our cells to make energy from food.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2009</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>C-Reactive Protein</measure>
    <time_frame>6 months</time_frame>
    <description>C-Reactive Protein (CRP) was measured by a clinical laboratory. Measuring the quantity of serum CRP is helpful in recognizing inflammatory states.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Anemia, Sickle Cell</condition>
  <arm_group>
    <arm_group_label>alpha-lipoic acid and acetyl-L-carnitine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>alpha-lipoic acid and acetyl-L-carnitine1400 mg tablet twice a day for 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1400 mg placebo tablet twice a day for 6 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>alpha-lipoic acid and acetyl-L-carnitine</intervention_name>
    <description>none to report</description>
    <arm_group_label>alpha-lipoic acid and acetyl-L-carnitine</arm_group_label>
    <other_name>Experimental</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Control</intervention_name>
    <description>none to report</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Proven diagnosis of sickle cell disease, either homozygous sickle disease or Hb S Beta&#xD;
             zero thalassemia genotype&#xD;
&#xD;
          -  Age at entry at least 14 years. Younger children will not be included since the&#xD;
             combination alpha-lipoic acid and acetyl-L-carnitine tablets are not available in a&#xD;
             smaller dose at this time.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  More than 3 packed red blood transfusions in the past 12 months&#xD;
&#xD;
          -  Coexisting illness that could contribute to inflammation. These include chronic&#xD;
             hepatitis, lupus, arthritis, inflammatory bowel disease, chronic osteomyelitis, and&#xD;
             other similar conditions.&#xD;
&#xD;
          -  Acute sickle cell disease related symptoms requiring a hospital visit in the past 4&#xD;
             weeks&#xD;
&#xD;
          -  Women who are pregnant, attempting to get pregnant, or breast feeding&#xD;
&#xD;
          -  Active participation in other investigational drug or device studies&#xD;
&#xD;
          -  Participants who start hydroxyurea or regular transfusion therapy during the course of&#xD;
             the study on the recommendation of their primary hematologist will be ineligible for&#xD;
             further participation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elliott Vichinsky, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCSF Benioff Children's Hospital Oakland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bruce N. Ames, Ph.D.</last_name>
    <role>Study Chair</role>
    <affiliation>UCSF Benioff Children's Hospital Oakland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ashutosh Lal, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>UCSF Benioff Children's Hospital Oakland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital &amp; Research Center Oakland</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>January 20, 2010</study_first_submitted>
  <study_first_submitted_qc>January 20, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 22, 2010</study_first_posted>
  <results_first_submitted>June 15, 2021</results_first_submitted>
  <results_first_submitted_qc>July 13, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">August 3, 2021</results_first_posted>
  <last_update_submitted>July 13, 2021</last_update_submitted>
  <last_update_submitted_qc>July 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Antioxidant</keyword>
  <keyword>Inflammation</keyword>
  <keyword>Sickle Cell Disease</keyword>
  <keyword>Oxidative Stress</keyword>
  <keyword>Cytokines</keyword>
  <keyword>anti-inflammatory</keyword>
  <keyword>Acetylcarnitine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia, Sickle Cell</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thioctic Acid</mesh_term>
    <mesh_term>Acetylcarnitine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>First subject was enrolled 08/10/09. Length of subject involvement was 7 months. Each subject was seen once a month at Children's Hospital &amp; Research Center Oakland</recruitment_details>
      <pre_assignment_details>Exclusions included those with 3 packed red blood transfusions in the past year, illness that could contribute to inflammation, acute sickle cell disease related symptoms requiring a hospital visit, those pregnant or breast feeding, or in other investigational drug or device studies, participants on hydroxyurea or a regular transfusion therapy.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Alpha-lipoic Acid and Acetyl-L-carnitine</title>
          <description>alpha-lipoic acid and acetyl-L-carnitine 1400 mg tablet twice a day for 6 months.&#xD;
alpha-lipoic acid and acetyl-L-carnitine: none to report</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>1400 mg placebo tablet twice a day for 6 months.&#xD;
Placebo: none to report</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Alpha-lipoic Acid and Acetyl-L-carnitine</title>
          <description>alpha-lipoic acid and acetyl-L-carnitine 1400 mg tablet twice a day for 6 months.&#xD;
alpha-lipoic acid and acetyl-L-carnitine: none to report</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>1400 mg placebo tablet twice a day for 6 months.&#xD;
Placebo: none to report</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="17"/>
            <count group_id="B2" value="20"/>
            <count group_id="B3" value="37"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>C-Reactive Protein</title>
        <description>C-Reactive Protein (CRP) was measured by a clinical laboratory. Measuring the quantity of serum CRP is helpful in recognizing inflammatory states.</description>
        <time_frame>6 months</time_frame>
        <population>Reason for discontinuation: started transfusions (2), alternative treatment (2), adverse events (4), subject preference (3).</population>
        <group_list>
          <group group_id="O1">
            <title>Alpha-lipoic Acid and Acetyl-L-carnitine</title>
            <description>alpha-lipoic acid and acetyl-L-carnitine 1400 mg tablet twice a day for 6 months.&#xD;
alpha-lipoic acid and acetyl-L-carnitine: none to report</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>1400 mg placebo tablet twice a day for 6 months.&#xD;
Placebo: none to report</description>
          </group>
        </group_list>
        <measure>
          <title>C-Reactive Protein</title>
          <description>C-Reactive Protein (CRP) was measured by a clinical laboratory. Measuring the quantity of serum CRP is helpful in recognizing inflammatory states.</description>
          <population>Reason for discontinuation: started transfusions (2), alternative treatment (2), adverse events (4), subject preference (3).</population>
          <units>mg/l</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.4" spread="20.9"/>
                    <measurement group_id="O2" value="6.8" spread="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Alpha-lipoic Acid and Acetyl-L-carnitine</title>
          <description>alpha-lipoic acid and acetyl-L-carnitine 1400 mg tablet twice a day for 6 months.&#xD;
alpha-lipoic acid and acetyl-L-carnitine: none to report</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>1400 mg placebo tablet twice a day for 6 months.&#xD;
Placebo: none to report</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Vaso-occlusive pain</sub_title>
                <counts group_id="E1" events="13" subjects_affected="6" subjects_at_risk="17"/>
                <counts group_id="E2" events="13" subjects_affected="9" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonia/Acute Chest Syndrome</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary Urgency/UTI</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory Symptoms</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="17"/>
                <counts group_id="E2" events="12" subjects_affected="9" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Ashutosh Lal, MD</name_or_title>
      <organization>Children's Hospital &amp; Research Center at Oakland</organization>
      <phone>5104283172</phone>
      <email>ashutosh.lal@ucsf.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

